ArticleOman journal of ophthalmology
Role of concurrent intravenous pulse steroids and orbital radiation in the management of thyroid eye disease.
Article in Oman journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze the outcomes of concurrent intravenous pulse steroids and orbital radiation (ORT) in thyroid eye disease (TED).
methodsIt was a retrospective interventional study. Medical records of patients presenting with clinically or radiologically active TED with diplopia were reviewed. All patients received concurrent ORT (20 Gy in 10 fractions) and 500 mg of pulsed intravenous methylprednisolone (IVMP). The response to treatment was assessed using International Thyroid Eye Disease Society-Vision, Inflammation, Strabismus, and Appearance scoring system.
resultsForty-eight orbits of 24 patients were included in the study. There was an equal male and female (12 each) distribution. The mean age at presentation was 53.6 ± 11.4 years (range: 38-73 years). The median duration of orbital disease was 5.5 months (range 1-96 months). Diplopia (22, 91.66%) was the most common presenting complaint. Posttreatment, there was a significant reduction in the mean inflammatory score (
conclusionConcurrent pulse IVMP with ORT is a safe and effective treatment modality for TED-related diplopia. An appropriate selection of cases along with a pretreatment magnetic resonance imaging to look for radiologically active disease aids in better planning and understanding of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.